Diagnostic agents selective against metalloproteases
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-051/00
A61M-036/14
A61K-049/00
A61K-049/08
A61K-049/10
A61K-049/22
A61K-051/04
출원번호
US-0000794
(2009-07-21)
등록번호
US-9480758
(2016-11-01)
우선권정보
EP-08160856 (2008-07-22)
국제출원번호
PCT/EP2009/059338
(2009-07-21)
§371/§102 date
20101222
(20101222)
국제공개번호
WO2010/010079
(2010-01-28)
발명자
/ 주소
Rossello, Armando
Nuti, Elisa
Avramova, Stanislava Ivanova
Uggeri, Fulvio
Maiocchi, Alessandro
출원인 / 주소
BRACCO IMAGING S.P.A.
대리인 / 주소
Vivicar Law, PLLC
인용정보
피인용 횟수 :
0인용 특허 :
44
초록▼
The invention relates to aryl-sulphonamido compounds endowed with affinity against metallo proteases MMP, having formula (I) below wherein R, R1, R2, R3, G and n have the meanings reported in the specification, properly labelled with diagnostic imaging moieties or even radiotherapeutic moieties. The
The invention relates to aryl-sulphonamido compounds endowed with affinity against metallo proteases MMP, having formula (I) below wherein R, R1, R2, R3, G and n have the meanings reported in the specification, properly labelled with diagnostic imaging moieties or even radiotherapeutic moieties. The invention also refers to the process for their preparation, to pharmaceutical compositions comprising them and to their use as diagnostic imaging agents or radiotherapeutic agents.
대표청구항▼
1. A compound comprising one or two residues of the metalloprotease inhibitor of formula (I), labelled with one optically active imaging moiety wherein: R is a group of formula —Ar—X—Ar′ (II) wherein Ar is a phenylene group, X is a single bond or a divalent linker selected from the group consisting
1. A compound comprising one or two residues of the metalloprotease inhibitor of formula (I), labelled with one optically active imaging moiety wherein: R is a group of formula —Ar—X—Ar′ (II) wherein Ar is a phenylene group, X is a single bond or a divalent linker selected from the group consisting of —O—, —S— and —NH— and Ar′ is a phenyl group; the said Ar and Ar′ being optionally substituted by one or more groups selected from the group consisting of straight or branched C1-C4 alkyl, straight or branched C1-C4 alkoxy, and halogen atoms;R1 is —Ra or —ORa wherein Ra is a group of formula (III) —(CH2)p—Z—(CH2)r—W (III)wherein p is 1 or 2; Z is a divalent linker selected from —O— and —NH—; r is 1 or 2; and W is phenyl or a 5 or 6 membered heterocycle, each of which is optionally substituted by one or more groups selected from —NH2, —COR′, —COOR′, —SO2NHR′ wherein R′ is or a straight or branched C1 to C4 alkyl group;one of R2 and R3 is H, and the other is a zinc binding group selected from —COOH and —CONHOH;G is a group of formula —(CH2)m—N(R4)(R5);R4 is a group selected from —CORc, —COORc, and —S(O)2Rc, wherein Rc is selected from aryl, straight or branched alkyl, and an arylalkyl group having from 1 to 4 carbon atoms in the alkyl chain;R5 is H;n is 2;m is 2;or a pharmaceutically acceptable salt thereof and wherein: (i) the optically active imaging moiety is a fluorescent moiety selected from the group consisting of fluorescin, 5-carboxyfluorescein, indocyanine green, Cy5, Cy5.5 and derivatives thereof including Cy5.5 mono NH ester and Cy5.5 bis NHS ester;(ii) the one or two residues of the metalloprotease inhibitor of formula (I) and the optically active imaging moiety are directly conjugated to each other and the conjugation occurs between a carboxyl or amino function of the optically active imaging moeity and the amino or carboxyl function of the metalloprotease inhibitors of formula (I) so as to form carboxamido bonds. 2. The compound according to claim 1 wherein the metalloprotease inhibitor or inhibitors of formula (I) are selected from the group consisting of: wherein R, n, R1, R2, R3, m, G, p, Z, r and W are as defined in claim 1 and the () represents the point of attachment with the rest of the molecule. 3. The compound according to claim 1 wherein R1 is ORa. 4. A contrast agent for optical imaging agent comprising a compound according to claim 1. 5. A pharmaceutical composition comprising, as an active ingredient, an effective amount of an imaging agent, the agent comprising one or two residues of the metalloprotease inhibitors of formula (I) labelled with one optically active imaging moiety or the physiologically acceptable salts thereof, as defined in claim 1, together with pharmaceutically acceptable carriers, diluents or excipients. 6. A method for the in vivo detection and diagnosis of pathological conditions associated with an impaired expression of metalloproteases in a mammal, wherein the method comprises administering to said mammal an effective amount of a compound as defined in claim 1, and detecting and diagnosing said pathological conditions associated with impaired expression of metalloproteases in said mammal. 7. A method for the in vitro detection and measurement of an impaired expression of metalloproteases in a biological sample, wherein the method comprises contacting the said biological sample with an effective amount of a compound as defined in claim 1, and detecting and measuring said impaired expression of metalloproteases in said biological sample. 8. A compound according to claim 1 selected from the group consisting of: 9. A compound selected from the group consisting of:
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (44)
Licha, Kai; Riefke, Bjorn; Semmler, Wolfhard; Wrasidlo, Wolfgang, Acid-labile and enzymatically divisible dye compounds for diagnosis with near infrared light and for therapy.
Linder Karen E. (Highland Park NJ) Nunn Adrian D. (Ringoes NJ) Ramalingam Kondareddiar (North Brunswick NJ), Boronic acid adducts of metal dioxime complexes useful in labelling proteins and other amine-containing compounds.
Nunn Adrian D. (Ringoes NJ) Linder Karen E. (Kingston NJ) Jurisson Silvia (Columbia MO) Eckelman William C. (Bethesda MD), Boronic acid adducts of rhenium dioxime and technetium-99m dioxime complexes containing a biochemically active group.
Toner John L. (Downingtown PA) Hilborn David A. (Henrietta NY) Murray Bruce J. (Walworth NY) Hossain Timothy Z. (Dallas TX), Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and.
Linder Karen (Kingston NJ) Nunn Adrian D. (Ringoes NJ) Nowotnik David P. (Flemington NJ) Ramalingam Kondareddiar (Dayton NJ) DiRocco Richard J. (Allentown NJ) Rumsey William L. (Wyndmoor PA) Pirro Jo, Diagnostic imaging methods using rhenium and technetium complexes containing a hypoxia-localizing moiety.
Pollak Alfred (Toronto CAX) Kirby Robert A. (Acton CAX) Dunn-Dufault Robert (Bramalea CAX), Hydrazino-type radionuclide chelators having an N3S configuration.
Schneider Michel (Troinex CHX) Yan Feng (Geneva CHX) Grenier ; deceased Pascal (late of Ambilly FRX by Nadine Garcel ; legal heir ) Puginier Jerome (Le Chable-Beaumont FRX) Barrau Marie-Bernadette (G, Long-lasting aqueous dispersions or suspensions of pressure-resistant gas-filled microvesicles and methods for the prepa.
Schneider Michel (Troinex CHX) Yan Feng (Genve CHX) Grenier ; deceased Pascal (late of Ambilly FRX by Nadine Garcel ; legal heir) Puginier Jrme (Le Chble-Beaumont FRX) Barrau Marie-Bernadette (Geneva, Long-lasting aqueous dispersions or suspensions of pressure-resistant gas-filled microvesicles and methods for the prepa.
Winchell Harry S. (Lafayette CA) Klein Joseph Y. (Haifa ILX) Cyjon Rosa L. (Haifa ILX) Simhon Eliot D. (Haifa ILX), MRI image enhancement using complexes of paramagnetic cations and amine ligands containing a mixture of phosphonate and.
Wedeking Paul W. ; Wager Ruth E. ; Arunachalam Thangavel ; Ramalingam Kondareddiar ; Linder Karen E. ; Ranganathan Ramachandran S. ; Nunn Adrian D. ; Raju Natarajan ; Tweedle Michael F., Metal complexes derivatized with folate for use in diagnostic and therapeutic applications.
Srinivasan Ananthachari (Kirkland WA) Fritzberg Alan R. (Edmonds WA) Jones David S. (Seattle WA), Metal radionuclide chelating compounds for improved chelation kinetics.
Scott E. Zook ; Raymond Dagnino, Jr. ; Michael E. Deason ; Steven L. Bender ; Michael J. Melnick, Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof.
Tweedle Michael F. ; Gaughan Glen T.,GBX ; Hagan James J., Method for imaging and radiopharmaceutical therapy using 1-substituted-4,7,10-tricarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs.
Ramalingam Kondareddiar (Dayton NJ) Raju Natarajan (Kendall Park NJ), Polyaza heteroatom-bearing ligands and metal complexes thereof for imaging or radiotherapy.
Sieving Paul F. (3166 Impala Dr. #5 San Jose CA 95117) Watson Alan D. (262A Rincon Ave. Campbell CA 95008) Quay Steven C. (428 Oakmead Pkwy. Sunnyvale CA 94086) Rocklage Scott M. (255 Cresci Rd. Los , Polychelants containing macrocyclic chelant moieties.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.